Isabl vs Yoneda Labs

Side-by-side comparison of AI visibility scores, market position, and capabilities

Isabl leads in AI visibility (45 vs 36)

Isabl

EmergingHealthcare

General

NYC YC W20 MSK Cancer Center spinout with FDA Breakthrough Device for whole-genome/transcriptome tumor profiling; $5M total (Two Sigma/NCI SBIR) competing with Foundation Medicine and Tempus AI for comprehensive genomic profiling in pediatric and rare cancers.

AI VisibilityBeta
Overall Score
C45
Category Rank
#824 of 1167
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
43
Perplexity
41
Gemini
54

About

Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss.

Full profile

Yoneda Labs

EmergingHealthcare

General

AI chemical reaction optimization with 95% accuracy for drug discovery synthesis parameters; $4.5M from Khosla Ventures and YC competing to automate pharmaceutical process chemistry development.

AI VisibilityBeta
Overall Score
D36
Category Rank
#999 of 1167
AI Consensus
53%
Trend
stable
Per Platform
ChatGPT
44
Perplexity
32
Gemini
30

About

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists with AI systems that determine optimal reaction parameters (temperature, solvent, catalyst, concentration) for new chemical synthesis routes, achieving 95% accuracy in suggesting effective conditions for small-scale trials. Founded in 2023 and backed by Khosla Ventures, 468 Capital, 500 Global, and Y Combinator with $4.5 million raised including a $4 million seed round in April 2024, Yoneda Labs brings mathematical category theory foundations (the name references Yoneda's lemma in category theory) to chemistry AI.

Full profile

AI Visibility Head-to-Head

45
Overall Score
36
#824
Category Rank
#999
59
AI Consensus
53
stable
Trend
stable
43
ChatGPT
44
41
Perplexity
32
54
Gemini
30
36
Claude
47
40
Grok
33

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.